Hims & Hers Stock Drops 30% After Novo Nordisk Ends Partnership
Hims & Hers stock dropped 33% after Novo Nordisk ended their partnership due to alleged illegal and deceptive practices related to the sale of compounded versions of Wegovy, citing patient safety concerns and pressure to prescribe the drug regardless of clinical appropriateness.